215 related articles for article (PubMed ID: 11419842)
1. Hepatic familial amyloidosis caused by a new mutation in the apolipoprotein AI gene: clinical and pathological features.
Caballería J; Bruguera M; Solé M; Campistol JM; Rodés J
Am J Gastroenterol; 2001 Jun; 96(6):1872-6. PubMed ID: 11419842
[TBL] [Abstract][Full Text] [Related]
2. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.
Booth DR; Tan SY; Booth SE; Tennent GA; Hutchinson WL; Hsuan JJ; Totty NF; Truong O; Soutar AK; Hawkins PN; Bruguera M; Caballería J; Solé M; Campistol JM; Pepys MB
J Clin Invest; 1996 Jun; 97(12):2714-21. PubMed ID: 8675681
[TBL] [Abstract][Full Text] [Related]
3. Livers from patients with apolipoprotein A-I amyloidosis are not suitable as "domino" donors.
Shaz BH; Lewis WD; Skinner M; Khettry U
Mod Pathol; 2001 Jun; 14(6):577-80. PubMed ID: 11406659
[TBL] [Abstract][Full Text] [Related]
4. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis.
Gregorini G; Izzi C; Obici L; Tardanico R; Röcken C; Viola BF; Capistrano M; Donadei S; Biasi L; Scalvini T; Merlini G; Scolari F
J Am Soc Nephrol; 2005 Dec; 16(12):3680-6. PubMed ID: 16221867
[TBL] [Abstract][Full Text] [Related]
5. Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26.
Vigushin DM; Gough J; Allan D; Alguacil A; Penner B; Pettigrew NM; Quinonez G; Bernstein K; Booth SE; Booth DR
Q J Med; 1994 Mar; 87(3):149-54. PubMed ID: 8208902
[TBL] [Abstract][Full Text] [Related]
6. Primary amyloidosis presenting with cholestasis and hyperkinetic portal hypertension.
Culafić D; Perisić M; Boricić I; Culafić-Vojinović V; Vukcević M
J Gastrointestin Liver Dis; 2007 Jun; 16(2):201-4. PubMed ID: 17592572
[TBL] [Abstract][Full Text] [Related]
7. Familial nephropathic non-neuropathic amyloidosis: clinical features, immunohistochemistry and chemistry.
Zalin AM; Jones S; Fitch NJ; Ramsden DB
Q J Med; 1991 Nov; 81(295):945-56. PubMed ID: 1808634
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic characteristics of hereditary apolipoprotein A-I amyloidosis in Ireland.
Traynor CA; Tighe D; O'Brien FJ; Leavey SF; Dorman AM; Denton MD; Magee C; Conlon PJ
Nephrology (Carlton); 2013 Aug; 18(8):549-54. PubMed ID: 23730806
[TBL] [Abstract][Full Text] [Related]
9. [Systemic amyloidosis presenting as cholestatic jaundice].
Jorquera Plaza F; Fernández Gundín MJ; Espinel Díez J; Muñoz Nnez F; Herrera Abián A; García Lagarto E; Olcoz Goñi JL
Rev Esp Enferm Dig; 1997 Nov; 89(11):859-61. PubMed ID: 9580204
[TBL] [Abstract][Full Text] [Related]
10. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein AI and apolipoprotein E mRNA expression in peripheral white blood cells from patients with orthotopic liver transplantation.
Martínez-López E; Nuño-González P; Ruiz-Madrigal B; Rodríguez-Sancho LC; Hernández-Nazará ZH; Segura-Ortega JE; Panduro A
Liver Int; 2007 Sep; 27(7):930-7. PubMed ID: 17696931
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg.
Gillmore JD; Stangou AJ; Tennent GA; Booth DR; O'Grady J; Rela M; Heaton ND; Wall CA; Keogh JA; Hawkins PN
Transplantation; 2001 Apr; 71(7):986-92. PubMed ID: 11349736
[TBL] [Abstract][Full Text] [Related]
13. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients.
Park MA; Mueller PS; Kyle RA; Larson DR; Plevak MF; Gertz MA
Medicine (Baltimore); 2003 Sep; 82(5):291-8. PubMed ID: 14530778
[TBL] [Abstract][Full Text] [Related]
14. [Primary amyloidosis of the liver].
Schmid PA; Burger HR; Spycher MA; Bühler H; Heitz PU
Dtsch Med Wochenschr; 1992 Jun; 117(26):1014-8. PubMed ID: 1618110
[TBL] [Abstract][Full Text] [Related]
15. Globular hepatic amyloid: an early stage in the pathway of amyloid formation: a study of 20 new cases.
Makhlouf HR; Goodman ZD
Am J Surg Pathol; 2007 Oct; 31(10):1615-21. PubMed ID: 17895765
[TBL] [Abstract][Full Text] [Related]
16. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene.
Benson MD; Liepnieks JJ; Yazaki M; Yamashita T; Hamidi Asl K; Guenther B; Kluve-Beckerman B
Genomics; 2001 Mar; 72(3):272-7. PubMed ID: 11401442
[TBL] [Abstract][Full Text] [Related]
17. The molecular biology and clinical features of amyloid neuropathy.
Benson MD; Kincaid JC
Muscle Nerve; 2007 Oct; 36(4):411-23. PubMed ID: 17554795
[TBL] [Abstract][Full Text] [Related]
18. Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis.
Gregorini G; Izzi C; Ravani P; Obici L; Dallera N; Del Barba A; Negrinelli A; Tardanico R; Nardi M; Biasi L; Scalvini T; Merlini G; Scolari F
Kidney Int; 2015 Jun; 87(6):1223-9. PubMed ID: 25565309
[TBL] [Abstract][Full Text] [Related]
19. AApoAIL75P amyloidosis causes cirrhosis-like appearance of the liver in the absence of laboratory or clinical signs of hepatic dysfunction.
Avsar Y; Spieker T; Kabar I; Roecken C; Wolters H; Schmidt H
Amyloid; 2014 Jun; 21(2):128-30. PubMed ID: 24669943
[No Abstract] [Full Text] [Related]
20. Polymorphic corneal amyloidosis: a disorder due to a novel mutation in the transforming growth factor beta-induced (BIGH3) gene.
Eifrig DE; Afshari NA; Buchanan HW; Bowling BL; Klintworth GK
Ophthalmology; 2004 Jun; 111(6):1108-14. PubMed ID: 15177960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
